Abstract
An overview of antibody-guided immunotherapy for neoplasia is presented. The diversity of the antibody molecule is highlighted, through the many sophisticated strategies proposed and employed, to overcome a number of problems impeding successful targeting. An update of radioimmunotherapy of ovarian cancer is presented and the exciting concepts that are introduced to the field of targeted cancer therapy by molecular biology and genetic engineering are addressed.